CoVigi phase IV multicentric trial evaluating COVID-19
vaccination adverse events and immune response dynamics in
cancer patients: First results on antibody and cellular
immunity

a 2021

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity

OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA et. al.

Basic information

Original name

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity

Authors

OBERMANNOVA, R., Regina DEMLOVÁ (203 Czech Republic, guarantor, belonging to the institution), I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ (203 Czech Republic), Kateřina PILÁTOVÁ (203 Czech Republic), Jiří NEVRLKA (203 Czech Republic), Hana LEJDAROVÁ (203 Czech Republic), B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK (203 Czech Republic), Jiří MAYER (203 Czech Republic), Igor KISS (203 Czech Republic) and Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic)

Edition

Congress of the European Society for Medical Oncology ESMO 2021, 2021

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

CoViGi

Impact factor

Impact factor: 51.769

RIV identification code

RIV/00216224:14110/21:00123104

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.1016/j.annonc.2021.08.1556

UT WoS

000700527703109

Keywords (in Czech)

SARS-CoV-2; klinické hodnocení; vakcíny; Pfizer-BioNTech; AstraZeneca; Johnson&Johnson; Moderna; nežádoucí účinky

Keywords in English

SARS-CoV-2; clinical trial; vaccines; Pfizer-BioNTech; AstraZeneca; Johnson & Johnson; Modern; adverse events

Abstract

V originále

SARS-CoV-2 infection may be a threat for those undergoing active anti-cancer therapy. We aim to study adverse events, efficacy, and immune response in Covid-19 vaccinated patients focusing on possibly interfering therapy.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ, Kateřina PILÁTOVÁ, Jiří NEVRLKA, Hana LEJDAROVÁ, B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK, Jiří MAYER, Igor KISS and Lenka ZDRAŽILOVÁ DUBSKÁ. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity. In Congress of the European Society for Medical Oncology ESMO 2021. 2021. ISSN 0923-7534. Available from: https://dx.doi.org/10.1016/j.annonc.2021.08.1556.

@proceedings{1807081,
   author = {Obermannova, R. and Demlová, Regina and Selingerova, I. and Doubek, M. and Okrouhlicova, D. and Mlnaříková, Marie and Pilátová, Kateřina and Nevrlka, Jiří and Lejdarová, Hana and Weinbergerova, B. and Cermakova, Z. and Valík, Dalibor and Mayer, Jiří and Kiss, Igor and Zdražilová Dubská, Lenka},
   booktitle = {Congress of the European Society for Medical Oncology ESMO 2021},
   doi = {http://dx.doi.org/10.1016/j.annonc.2021.08.1556},
   keywords = {SARS-CoV-2; clinical trial; vaccines; Pfizer-BioNTech; AstraZeneca; Johnson & Johnson; Modern; adverse events},
   language = {eng},
   note = {CoVigi},
   title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity},
   url = {https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext},
   year = {2021}
}

TY  - CONF
ID  - 1807081
AU  - Obermannova, R. - Demlová, Regina - Selingerova, I. - Doubek, M. - Okrouhlicova, D. - Mlnaříková, Marie - Pilátová, Kateřina - Nevrlka, Jiří - Lejdarová, Hana - Weinbergerova, B. - Cermakova, Z. - Valík, Dalibor - Mayer, Jiří - Kiss, Igor - Zdražilová Dubská, Lenka
PY  - 2021
TI  - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
N1  - CoVigi
KW  - SARS-CoV-2
KW  - clinical trial
KW  - vaccines
KW  - Pfizer-BioNTech
KW  - AstraZeneca
KW  - Johnson & Johnson
KW  - Modern
KW  - adverse events
UR  - https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext
N2  - SARS-CoV-2 infection may be a threat for those undergoing active anti-cancer therapy. We aim to study adverse events, efficacy, and immune response in Covid-19 vaccinated patients focusing on possibly interfering therapy.
ER  -

OBERMANNOVA, R., Regina DEMLOVÁ, I. SELINGEROVA, M. DOUBEK, D. OKROUHLICOVA, Marie MLNAŘÍKOVÁ, Kateřina PILÁTOVÁ, Jiří NEVRLKA, Hana LEJDAROVÁ, B. WEINBERGEROVA, Z. CERMAKOVA, Dalibor VALÍK, Jiří MAYER, Igor KISS and Lenka ZDRAŽILOVÁ DUBSKÁ. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity. In \textit{Congress of the European Society for Medical Oncology ESMO 2021}. 2021. ISSN~0923-7534. Available from: https://dx.doi.org/10.1016/j.annonc.2021.08.1556.

Detailed Information on Publication Record